(A) Lytic activity of anti–MAGE-A3.A1 CTL clone 434/1 and anti–MAGE-A3.A2 CTL clone 297/22 against myeloma cell lines EJM and U266. Expression of gene MAGE-A3 was assessed by RT-PCR by using the same procedure as for the primary myeloma samples. (B) TNF- release by the same CTL clones after incubation with the same myeloma cell lines.